selinexor (KPT-330)
14-005
Phase 2 small_molecule completed
Quick answer
selinexor (KPT-330) for Myelodysplastic Syndromes is a Phase 2 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Karyopharm Therapeutics
- Indication
- Myelodysplastic Syndromes
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed